Ongoing clinical trials continue to investigate the long-term neurological effects of GLP-1 receptor agonists, and future research may provide further clarity on their role in cognitive health
[3] This is a known effect and not cause for concern
While excessive oxidative damage contributes to cancer-related complications, a strategic modulation of lipid peroxidation offers opportunities for therapeutic interventions, such as ferroptosis induction to selectively target cancer cells
So, even in the 1990s, scientists were thinking that GLP-1 agonists could be used for weight loss
When GLP-1 attaches to its receptors in the brain, it triggers a feeling of fullness, leading to reduced cravings and decreased food consumption
Regulatory Outlook and Potential NHS Availability Retatrutide has not been submitted for regulatory approval in the UK